Oveporexton
As of the edition of 20 October 2026, Oveporexton is a small molecule: marketed, first approved in 2026 (US); acts on HCRTR2; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2026
- Kind
- Small molecule
- Brand name
- Orzeyful
- First approved
- 5 August 2026 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- TAKEDA PHARMS USA
- Registered trials
- 1, 0 stopped early
- Disease areas
- Mental health; Nervous system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| HCRTR2 | Orexin receptor type 2 | O43614 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 1 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Takeda | Lead sponsor of trials | 2024 to now |